Related Experiment Videos
Topical flurbiprofen therapy in vernal keratoconjunctivitis
R N Sud1, R S Greval, R S Bajwa
1Dayanand Medical College & Hospital, Ludhiana.
Indian Journal of Medical Sciences
|September 1, 1995
Summary
Topical flurbiprofen is effective for vernal keratoconjunctivitis but less so than betamethasone. Flurbiprofen is recommended first due to steroid side effects, with betamethasone as a backup if needed.
Area of Science:
- Ophthalmology
- Clinical Pharmacology
Background:
- Vernal keratoconjunctivitis (VKC) is a recurrent allergic eye condition.
- Steroidal anti-inflammatory drugs are commonly used but carry risks of side effects with prolonged use.
Purpose of the Study:
- To evaluate the efficacy of topical flurbiprofen in treating VKC.
- To compare the therapeutic effect of flurbiprofen with betamethasone.
Main Methods:
- A clinical study involving 90 patients diagnosed with VKC.
- Comparative analysis of treatment outcomes between flurbiprofen and betamethasone eye drops.
Main Results:
- Flurbiprofen demonstrated efficacy in managing VKC symptoms.
- Betamethasone showed a higher degree of effectiveness compared to flurbiprofen.
Conclusions:
- Topical flurbiprofen is a viable treatment option for VKC.
- Due to potential steroid-related side effects, flurbiprofen should be considered as a first-line treatment, with betamethasone reserved for cases unresponsive to flurbiprofen.